Glimepiride Reduces CD14 Expression and Cytokine Secretion from Macrophages

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2014 Jun 23

PMID 24952384

Citations 18

Authors

Victoria Ingham

Alun Williams

Clive Bate

Affiliations

Soon will be listed here.

Abstract

Background: Activated microglia are associated with deposits of aggregated proteins within the brains of patients with Alzheimer's disease (AD), Parkinson's disease (PD) and prion diseases. Since the cytokines secreted from activated microglia are thought to contribute to the pathogenesis of these neurodegenerative diseases, compounds that suppress cytokine production have been identified as potential therapeutic targets. CD14 is a glycosylphosphatidylinositol (GPI)- anchored protein that is part of a receptor complex that mediates microglial responses to peptides that accumulate in prion disease (PrP82-146), AD (amyloid-β (Aβ)42) and PD (α-synuclein (αSN)). As some GPI-anchored proteins are released from cells by treatment with glimepiride, a sulphonylurea used for the treatment of diabetes, the effects of glimepiride upon CD14 expression and cytokine production from cultured macrophages were studied.

Methods: RAW 264 cells and microglial cells were treated with glimepiride or phosphatidylinositol (PI)-phospholipase C (PLC) and the expression of cell receptors was analysed by ELISA and immunoblot. Treated cells were subsequently incubated with Aβ42, αSN, PrP82-146 or lipopolysaccharide (LPS) and the amounts of Toll-like receptor (TLR)-4, tumour necrosis factor (TNF), interleukin (IL)-1 and IL-6 measured.

Results: Glimepiride released CD14 from RAW 264 cells and microglial cells. Pre-treatment with glimepiride significantly reduced TNF, IL-1 and IL-6 secretion from RAW 264 and microglial cells incubated with LPS, Aβ42, αSN and PrP82-146. Glimepiride also reduced the LPS, Aβ42, αSN and PrP82-146-induced translocation of TLR-4 into membrane rafts that is associated with cell activation. These effects of glimepiride were also seen after digestion of RAW 264 cells with PI-phospholipase C (PLC). In addition, the effects of glimepiride were blocked by pharmacological inhibition of GPI-PLC. The cytokine production was CD14-dependent; it was reduced in microglia from CD14 knockout mice and was blocked by antiserum to CD14.

Conclusions: RAW 264 and microglial cell responses to Aβ1-42, αSN, PrP82-146 and LPS are dependent upon CD14 expression. Glimepiride induced the shedding of CD14 from cells by activation of GPI-PLC and consequently reduced cytokine production in response to Aβ42, αSN, PrP82-146 and LPS. These results suggest that glimepiride acts as a novel anti-inflammatory agent that could modify the progression of neurodegenerative diseases.

Citing Articles

Pro-Oxidative and Inflammatory Actions of Extracellular Hemoglobin and Heme: Molecular Events and Implications for Alzheimer's and Parkinson Disease.

Campomayor N, Kim H, Kim M Biomol Ther (Seoul). 2025; 33(2):235-248.

PMID: 39962769 PMC: 11893490. DOI: 10.4062/biomolther.2024.224.

Antidiabetic drugs in Parkinson's disease.

Aguirre-Vidal Y, Montes S, Mota-Lopez A, Navarrete-Vazquez G Clin Park Relat Disord. 2024; 11:100265.

PMID: 39149559 PMC: 11325349. DOI: 10.1016/j.prdoa.2024.100265.

(Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins I: Localization at Plasma Membranes and Extracellular Compartments.

Muller G, Muller T Biomolecules. 2023; 13(5).

PMID: 37238725 PMC: 10216265. DOI: 10.3390/biom13050855.

Microglia Mediated Neuroinflammation in Parkinson's Disease.

Isik S, Yeman Kiyak B, Akbayir R, Seyhali R, Arpaci T Cells. 2023; 12(7).

PMID: 37048085 PMC: 10093562. DOI: 10.3390/cells12071012.

Transfer of Proteins from Cultured Human Adipose to Blood Cells and Induction of Anabolic Phenotype Are Controlled by Serum, Insulin and Sulfonylurea Drugs.

Muller G, Muller T Int J Mol Sci. 2023; 24(5).

PMID: 36902257 PMC: 10003403. DOI: 10.3390/ijms24054825.

References

Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G . Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol. 2007; 205(2):295-312. DOI: 10.1016/j.expneurol.2007.02.008. View

Tsumura K . Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract. 1995; 28 Suppl:S147-9. DOI: 10.1016/0168-8227(95)01104-l. View

Bate C, Boshuizen R, Williams A . Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J Neuroimmunol. 2005; 170(1-2):62-70. DOI: 10.1016/j.jneuroim.2005.08.021. View

Terreni L, De Simoni M . Role of the brain in interleukin-6 modulation. Neuroimmunomodulation. 1998; 5(3-4):214-9. DOI: 10.1159/000026339. View

Mayor S, Rao M . Rafts: scale-dependent, active lipid organization at the cell surface. Traffic. 2004; 5(4):231-40. DOI: 10.1111/j.1600-0854.2004.00172.x. View

Song M, Jin J, Lim J, Kou J, Pattanayak A, Rehman J . TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation. 2011; 8:92. PMC: 3169468. DOI: 10.1186/1742-2094-8-92. View

Duan W, Zhou J, Zhang S, Zhao K, Zhao L, Ogata K . ESeroS-GS modulates lipopolysaccharide-induced macrophage activation by impairing the assembly of TLR-4 complexes in lipid rafts. Biochim Biophys Acta. 2011; 1813(5):772-83. DOI: 10.1016/j.bbamcr.2011.01.019. View

Triantafilou M, Miyake K, Golenbock D, Triantafilou K . Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci. 2002; 115(Pt 12):2603-11. DOI: 10.1242/jcs.115.12.2603. View

McCoy M, Tansey M . TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008; 5:45. PMC: 2577641. DOI: 10.1186/1742-2094-5-45. View

10.

Haziot A, Chen S, Ferrero E, Low M, Silber R, Goyert S . The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol. 1988; 141(2):547-52. View

11.

Righi M, Mori L, De Libero G, Sironi M, Biondi A, Mantovani A . Monokine production by microglial cell clones. Eur J Immunol. 1989; 19(8):1443-8. DOI: 10.1002/eji.1830190815. View

12.

Danesh F, Anel R, Zeng L, Lomasney J, Sahai A, Kanwar Y . Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz). 2003; 51(3):139-48. View

13.

Heine H, Ulmer A, Lentschat A, Hamann L . Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex. J Endotoxin Res. 2001; 7(3):227-31. View

14.

Wyss-Coray T . Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med. 2006; 12(9):1005-15. DOI: 10.1038/nm1484. View

15.

Jin J, Shie F, Liu J, Wang Y, Davis J, Schantz A . Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation. 2007; 4:2. PMC: 1766347. DOI: 10.1186/1742-2094-4-2. View

16.

Barger S, Horster D, Furukawa K, GOODMAN Y, Krieglstein J, Mattson M . Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A. 1995; 92(20):9328-32. PMC: 40978. DOI: 10.1073/pnas.92.20.9328. View

17.

Breitner J, Haneuse S, Walker R, Dublin S, Crane P, Gray S . Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009; 72(22):1899-905. PMC: 2690966. DOI: 10.1212/WNL.0b013e3181a18691. View

18.

Gri G, Molon B, Manes S, Pozzan T, Viola A . The inner side of T cell lipid rafts. Immunol Lett. 2004; 94(3):247-52. DOI: 10.1016/j.imlet.2004.05.012. View

19.

Jick H, Zornberg G, Jick S, Seshadri S, Drachman D . Statins and the risk of dementia. Lancet. 2000; 356(9242):1627-31. DOI: 10.1016/s0140-6736(00)03155-x. View

20.

Mattson M, Barger S, Furukawa K, Bruce A, Wyss-Coray T, Mark R . Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev. 1997; 23(1-2):47-61. DOI: 10.1016/s0165-0173(96)00014-8. View